BeyondSpring (NASDAQ:BYSI) Stock Crosses Below 50 Day Moving Average – Here’s Why

BeyondSpring Inc. (NASDAQ:BYSI)’s share price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.61 and traded as low as $1.29. BeyondSpring shares last traded at $1.44, with a volume of 23,219 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

BeyondSpring Stock Performance

The company has a market capitalization of $59.21 million, a price-to-earnings ratio of -10.29 and a beta of 0.41. The business’s 50-day simple moving average is $1.61 and its 200-day simple moving average is $1.69.

BeyondSpring (NASDAQ:BYSI) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49.

Hedge Funds Weigh In On BeyondSpring

An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC lifted its position in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 16.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 368,682 shares of the company’s stock after purchasing an additional 53,198 shares during the quarter. Geode Capital Management LLC owned 0.91% of BeyondSpring worth $601,000 at the end of the most recent reporting period. 40.29% of the stock is currently owned by hedge funds and other institutional investors.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.